
USDOT Seeks Comments on Proposed Changes to Invalid Specimen Procedures
Federal drug-testing procedures can change as regulations are reviewed and organizations submit recommendations for how testing programs should operate.
On October 1, 2026, the U.S. Department of Transportation (USDOT) published a notification announcing receipt of a petition for rulemaking concerning 49 CFR Part 40, the federal regulations governing transportation workplace drug and alcohol testing programs.
The petition asks DOT to consider changes to procedures involving certain invalid specimen determinations and situations in which a medical condition may affect an employee’s ability to provide a valid urine specimen.
DOT is currently accepting public comments as it considers whether to grant the petition and begin a rulemaking process. Comments are due November 2, 2026, under Docket DOT-OST-2026-3664.
What Does the Petition Request?
The petition, submitted to DOT on February 27, 2026, proposes changes to how certain medical explanations for abnormal specimen validity findings would be considered.
One proposed change would establish a defined period of no more than 72 hours for an employee to submit medical documentation supporting a plausible medical explanation for an abnormal specimen validity finding.
The petition also addresses situations involving diagnosed urological conditions or functional voiding disorders, including psychogenic urinary retention, commonly known as paruresis.
In those circumstances, the proposed language would have the Medical Review Officer (MRO) consider consulting with a licensed urologist or licensed mental health professional familiar with the condition before making a final determination.
These provisions are part of the petition’s requested changes. They are not currently new federal requirements.
This Is Not Yet a Change to DOT Regulations
That distinction matters.
USDOT’s October 1 notice is a notification of a petition for rulemaking and request for comments. DOT is asking for information that could help the department determine whether to grant the petition.
The publication of the notice does not mean that the requested changes have been adopted.
Organizations involved in DOT-regulated drug testing therefore should not treat the petition’s proposed procedures as current requirements. Instead, the November 2 comment deadline provides an opportunity for interested parties to submit information and perspectives to DOT while the petition is being considered.
Why Drug-Testing Laboratories Should Pay Attention
A drug-testing program involves more than the analysis of a specimen.
Depending on the program, the process can involve specimen collection, laboratory testing, Medical Review Officers, employers, government agencies, reporting systems, and other organizations.
When federal testing procedures are considered for modification, organizations involved in the testing process may need to understand what the proposed changes could mean for their respective responsibilities if those changes eventually move forward.
For laboratories, that makes regulatory awareness an important part of operating within a changing drug-testing environment.
The laboratory also depends on the equipment, supplies, service, technical support, and systems necessary to maintain its testing operations.
Supporting the Laboratories Behind Drug Testing
DTPM has supported laboratories since 1993 and provides laboratory equipment, supplies, services, and program management solutions to organizations across the United States.
DTPM serves a range of laboratory environments, including drug courts, treatment centers, physician offices, and reference laboratories. Its laboratory support includes equipment and instrumentation, preventive maintenance, equipment service, technical support, training, laboratory setup and management, supplies, and LIS/LIMS solutions.
For laboratories supporting drug-testing programs, those resources are part of the infrastructure needed to keep laboratory operations moving.
Regulatory developments are only one consideration. Laboratories must also manage the everyday demands of maintaining equipment, obtaining supplies, addressing technical issues, and supporting the testing programs that depend on their services.
What Happens Next?
For now, the USDOT petition remains under consideration.
The public comment period closes November 2, 2026, and DOT will consider the comments and other information received as it determines whether to grant the petition and proceed with rulemaking.
Until any changes are formally adopted, the existing federal requirements remain in effect.
For laboratories and organizations involved in regulated drug testing, this is a development worth monitoring as the process moves forward.
DTPM continues to support laboratories with the equipment, supplies, service, technical support, and laboratory solutions they need to maintain their testing operations.
Learn more about DTPM’s laboratory equipment, collection and testing supplies, preventive maintenance services, technical support, and laboratory solutions at DTPM.com.
U.S. Department of Transportation, Petition for Rulemaking; Invalid Specimen Determinations, Federal Register, October 1, 2026. Docket No. DOT-OST-2026-3664.
